Dystrophic epidermolysis bullosa (DEB) is a devastating rare genetic skin disorder characterized by fragile and blistering skin due to defects in collagen production. The treatment landscape for DEB remains challenging, with no cure currently available. Existing therapies mainly focus on symptom management and improving quality of life for patients